Is early caffeine therapy safe and effective for ventilated preterm infants?

J Perinatol

Perinatal Institute, Division of Neonatology, Cincinnati Children's Hospital, Cincinnati, OH, USA.

Published: May 2019

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41372-019-0336-7DOI Listing

Publication Analysis

Top Keywords

early caffeine
4
caffeine therapy
4
therapy safe
4
safe effective
4
effective ventilated
4
ventilated preterm
4
preterm infants?
4
early
1
therapy
1
safe
1

Similar Publications

With an incidence of 2-5 per million adults, cerebral venous and sinus thrombosis (CVST) is a rarity in the spectrum of cerebrovascular diseases. The etiology and symptomatic presentation are heterogeneous and diverse. CSVT is, therefore, often underdiagnosed.

View Article and Find Full Text PDF

Yerba mate (YM, ) is an economically important crop marketed for the elaboration of mate, the third-most widely consumed caffeine-containing infusion worldwide. Here, we report the first genome assembly of this species, which has a total length of 1.06 Gb and contains 53,390 protein-coding genes.

View Article and Find Full Text PDF

Introduction: Non-invasive respiratory support strategies have evolved to avoid bronchopulmonary dysplasia (BPD) in preterm infants. However, consensus on the best treatment strategy remains lacking. This study aims to investigate current practices and variations in primary respiratory support for extremely preterm neonates across neonatal intensive care units (NICUs) in the Netherlands.

View Article and Find Full Text PDF

No previous study has examined the association between coffee and caffeine intake and odds of functional dyspepsia (FD). The aim of this study was to investigate the association between coffee and caffeine intake and odds of FD and its components in a large sample of Iranian adults. In this cross-sectional study on 3362 adults aged 18-55 years, a validated food frequency questionnaire (DS-FFQ) was used to assess dietary intakes.

View Article and Find Full Text PDF

Seralutinib, an inhaled, small-molecule tyrosine kinase inhibitor in clinical development for the treatment of pulmonary arterial hypertension (PAH), was evaluated for its potential as a perpetrator or victim of a metabolic and transporter-based drug-drug interactions in 2 phase 1 studies. In study 1, 24 participants received a cocktail of probe substrates: caffeine (CYP1A2), montelukast (CYP2C8), flurbiprofen (CYP2C9), midazolam (CYP3A), and pravastatin (OATP1B1/1B3), plus digoxin (P-gp) with or without seralutinib. In study 2, 19 participants received seralutinib with/without itraconazole, a strong CYP3A inhibitor, or fosaprepitant, a weak CYP3A inhibitor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!